{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:28:40Z","timestamp":1761895720066},"reference-count":40,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2013,7,9]],"date-time":"2013-07-09T00:00:00Z","timestamp":1373328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2013,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Patients with aggressive non\u2010<jats:styled-content style=\"fixed-case\">H<\/jats:styled-content>odgkin lymphoma (<jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>) who relapse after autologous stem cell transplantation (<jats:styled-content style=\"fixed-case\">ASCT<\/jats:styled-content>) have a poor prognosis. Additional therapy is often poorly tolerated, and new treatment modalities are needed. This efficacy and safety study was a retrospective analysis of two phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> trials (<jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>\u2010002 and <jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>\u2010003) that studied single\u2010agent lenalidomide in patients with relapsed\/refractory aggressive <jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content> with prior (<jats:italic>n<\/jats:italic>\u00a0=\u00a087) compared with no prior <jats:styled-content style=\"fixed-case\">ASCT<\/jats:styled-content> (<jats:italic>n<\/jats:italic>\u00a0=\u00a0179). The overall response rate in the <jats:styled-content style=\"fixed-case\">ASCT<\/jats:styled-content> group was 39% [14% complete response (<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>)], including 29% in patients with diffuse large <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>\u2010cell lymphoma, 63% in mantle cell lymphoma, and 60% in transformed lymphoma. The timing of transplant relative to receiving lenalidomide had no effect on outcomes. Median progression\u2010free survival for the <jats:styled-content style=\"fixed-case\">ASCT<\/jats:styled-content> group was 3\u00b77\u00a0months (16\u00b79\u00a0months for patients in <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>; 7\u00b73\u00a0months for partial responders) at a median 12\u00b75\u2010month follow\u2010up. Median response duration was 7\u00b79\u00a0months. Regardless of prior <jats:styled-content style=\"fixed-case\">ASCT<\/jats:styled-content>, lenalidomide monotherapy was efficacious in heavily pretreated patients with aggressive, relapsed\/refractory <jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>, with a safety profile that was consistent with prior studies of single\u2010agent lenalidomide.<\/jats:p>","DOI":"10.1111\/bjh.12449","type":"journal-article","created":{"date-parts":[[2013,7,9]],"date-time":"2013-07-09T10:36:06Z","timestamp":1373366166000},"page":"639-647","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Single\u2010agent lenalidomide is active in patients with relapsed or refractory aggressive non\u2010Hodgkin lymphoma who received prior stem cell transplantation"],"prefix":"10.1111","volume":"162","author":[{"given":"Julie M.","family":"Vose","sequence":"first","affiliation":[{"name":"University of Nebraska Medical Center Omaha NE USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[{"name":"Mayo Clinic Rochester MN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myron S.","family":"Czuczman","sequence":"additional","affiliation":[{"name":"Roswell Park Cancer Institute Buffalo NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"Institute of Haematology and Oncology Seragnoli University of Bologna Bologna Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig B.","family":"Reeder","sequence":"additional","affiliation":[{"name":"Mayo Clinic Arizona Scottsdale AZ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph M.","family":"Tuscano","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center Sacramento CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izidore S.","family":"Lossos","sequence":"additional","affiliation":[{"name":"University of Miami School of Medicine Miami FL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju","family":"Li","sequence":"additional","affiliation":[{"name":"Celgene Corporation Summit NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Pietronigro","sequence":"additional","affiliation":[{"name":"Celgene Corporation Summit NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[{"name":"Mayo Clinic Rochester MN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,7,9]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq035"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276246"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052638"},{"key":"e_1_2_8_6_1","first-page":"A1","article-title":"Clinical Roundtable Monograph: recent advances in NHL. Highlights from the 51st ASH Annual Meeting and Exposition, December 5\u20138, 2009, New Orleans, Louisiana","volume":"8","author":"Czuczman M.S.","year":"2010","journal-title":"Clinical Advances in Hematology and Oncology"},{"key":"e_1_2_8_7_1","doi-asserted-by":"crossref","unstructured":"Dutia M. DeRoock I. Chee K. O'Donnell R.T. Quirch C. Reed\u2010Pease C.&Tuscano J.M.(2009)R2: Preliminary results of a phase II study of lenalidomide and rituximab in relapsed\/ refractory indolent non\u2010Hodgkin's lymphoma. Blood (ASH Annual Meeting Abstracts) 114 1679.","DOI":"10.1182\/blood.V114.22.1679.1679"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0231"},{"key":"e_1_2_8_9_1","doi-asserted-by":"crossref","unstructured":"Gaidarova S. Li J. Corral L.G. Glezer E. Schafer P.H. Xie W. Lopez\u2010Girona A. Cheson B.D.&Bennett B.(2009)Lenalidomide alone and in combination with rituximab enhances NK cell immune synapse formation in chronic lymphocytic leukemia (CLL) cells in vitro through activation of Rho and Rac1 GTPases. ASH Annual Meeting Abstracts 114 3441.","DOI":"10.1182\/blood.V114.22.3441.3441"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.01.010"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0901166106"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.1003"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07626.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj996"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0577"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704214"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-011-1227-y"},{"key":"e_1_2_8_20_1","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel N.","year":"1966","journal-title":"Cancer Chemotherapy Reports"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181c810b6"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.165"},{"key":"e_1_2_8_23_1","doi-asserted-by":"crossref","unstructured":"Nowakowski G.S. LaPlant B.R. Reeder C. Foran J.M. Porrata L.F. Macon W.R. Johnston P.B. Rivera C.E. Habermann T.M. Inwards D.J. Micallef I.N. Nelson G.D. Ansell S.M.&Witzig T.E.(2012)Combination of lenalidomide with R\u2010CHOP (R2CHOP) is well\u2010tolerated and effective as initial therapy for aggressive B\u2010cell lymphomas \u2013 A phase II study. Blood (ASH Annual Meeting Abstracts) 120 Abstract689.","DOI":"10.1182\/blood.V120.21.689.689"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703888"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/00130404-200209000-00007"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70002-0"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70235-2"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-217687"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06841.x"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-111708"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701944"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-009-0808-5"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-2317"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.8.2142.2142"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2003.09.015"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.3429"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.1169"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq626"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4405"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0512-7"},{"key":"e_1_2_8_41_1","doi-asserted-by":"crossref","unstructured":"Zinzani P.L. Vose J.M. Czuczman M.S. Reeder C. Haioun C. Polikoff J. Tilly H. Pietronigro D. Ervin\u2010Haynes A. Li J.&Witzig T.E.(2012)Phase II multicenter study of the safety and efficacy of single\u2010agent lenalidomide in subjects with relapsed\/refractory mantle cell lymphoma: Long\u2010term follow\u2010up analysis of the NHL\u2010003 study. Blood (ASH Annual Meeting Abstracts) 120 2738.","DOI":"10.1182\/blood.V120.21.2738.2738"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.12449","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.12449","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T02:51:41Z","timestamp":1696301501000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.12449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,9]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.1111\/bjh.12449"],"URL":"https:\/\/doi.org\/10.1111\/bjh.12449","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,9]]},"assertion":[{"value":"2013-05-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-05-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-07-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}